Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2926
Hafnia
HAFN
$3.8B
| $1.94M | ﹤0.01% |
363,459
+95,274
| +36% | +$568K |
|
2927
Hallador Energy
HNRG
$730M
| $1.93M | ﹤0.01% |
101,495
-17,114
| -14% | -$347K |
|
2928
Protolabs
PRLB
$2.21B
| $1.93M | ﹤0.01% |
38,149
+3,899
| +11% | +$199K |
|
|
KE
2929
Kimball Electronics
KE
$626M
| $1.93M | ﹤0.01% |
69,334
+498
| +0.7% | +$14.4K |
|
2930
Phreesia
PHR
$780M
| $1.93M | ﹤0.01% |
113,941
+21,605
| +23% | +$446K |
|
2931
SELLAS Life Sciences
SLS
$2.5B
| $1.93M | ﹤0.01% |
511,034
+328,354
| +180% | +$638K |
|
|
PRA
2932
DELISTED
ProAssurance
PRA
| $1.92M | ﹤0.01% |
79,644
+7,475
| +10% | +$180K |
|
2933
Grindr
GRND
$2.74B
| $1.92M | ﹤0.01% |
142,054
-5,097
| -3% | -$69.3K |
|
2934
Avalo Therapeutics
AVTX
$1.04B
| $1.92M | ﹤0.01% |
105,814
+96,468
| +1,032% | +$1.63M |
|
2935
Gentherm
THRM
$1.32B
| $1.92M | ﹤0.01% |
52,758
+2,240
| +4% | +$80.7K |
|
2936
CALL
Coca-Cola
KO
$376B
| $1.92M | ﹤0.01% |
27,400
+3,200
| +13% | +$223K |
|
2937
Emergent Biosolutions
EBS
$230M
| $1.91M | ﹤0.01% |
154,892
-25,258
| -14% | -$271K |
|
2938
Marten Transport
MRTN
$1.24B
| $1.91M | ﹤0.01% |
167,887
+26,098
| +18% | +$277K |
|
2939
U-Haul Holding Co
UHAL
$14.4B
| $1.9M | ﹤0.01% |
37,772
+24,915
| +194% | +$1.33M |
|
2940
Cogent Communications
CCOI
$530M
| $1.9M | ﹤0.01% |
88,314
+22,741
| +35% | +$671K |
|
2941
Bumble
BMBL
$359M
| $1.9M | ﹤0.01% |
532,896
-848,038
| -61% | -$3.76M |
|
2942
Pagaya Technologies
PGY
$1.79B
| $1.9M | ﹤0.01% |
+91,008
| New | +$2.32M |
|
2943
CALL
Rapid7
RPD
$929M
| $1.9M | ﹤0.01% |
125,000
-30,000
| -19% | -$494K |
|
2944
Klaviyo
KVYO
$5.47B
| $1.89M | ﹤0.01% |
58,292
+12,459
| +27% | +$349K |
|
2945
Sumitomo Mitsui Financial
SMFG
$167B
| $1.89M | ﹤0.01% |
97,896
+86,356
| +748% | +$1.5M |
|
|
ORC
2946
Orchid Island Capital
ORC
$1.32B
| $1.89M | ﹤0.01% |
262,543
+58,917
| +29% | +$429K |
|
2947
AMC Entertainment Holdings
AMC
$2.35B
| $1.89M | ﹤0.01% |
1,209,841
-1,942,202
| -62% | -$4.63M |
|
2948
US Physical Therapy
USPH
$1.24B
| $1.89M | ﹤0.01% |
24,161
+2,823
| +13% | +$229K |
|
2949
Olin
OLN
$2.17B
| $1.88M | ﹤0.01% |
90,243
-69,457
| -43% | -$1.5M |
|
2950
TETRA Technologies
TTI
$1.25B
| $1.88M | ﹤0.01% |
200,371
+15,307
| +8% | +$118K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.